Text written in Basque and translated automatically by Elia without any subsequent editing. SEE ORIGINAL

[Timed trial for the development of anti-Ebola treatments and vaccines]

Researchers are working to offer effective treatments and vaccines against Ebola, as well as against the variant that has now caused the outbreak: Bundibugyo. It is reported by Nature that two WHO-sponsored trials are underway. Both are awaiting authorization from the Democratic Republic of the Congo and Uganda, and it is likely that some more will be authorized during this same outbreak.

“They are awaiting permits from the Democratic Republic of the Congo and Uganda and are likely to allow some more.”

Both trials are of treatments and both are being developed by U.S. pharmaceutical companies. The first, remdebisir, was tested against the Zaire variant during its appearance in 2018-2019. The other, MBP134, was tested against the Susan variant in Uganda during the 2022 outbreak. They were then unable to demonstrate efficacy, but studies with primates have yielded good results.

On the other hand, mRNA vaccines are also being tested. For example, the PNAS magazine has just published the results of one they have developed in China. It would be valid for all variants, but for now it has only been tested in mice.